CN Patent

CN120393011A — Smoc2的诊断和制药用途

Assigned to Renmin Hospital of Wuhan University · Expires 2025-08-01 · 1y expired

What this patent protects

本发明属于生物医药技术领域，具体涉及SMOC2的诊断和制药用途。相较于正常人，临床心力衰竭病人心脏中SMOC2基因表达水平升高，SMOC2作为标志物在心肌肥厚和心力衰竭诊断中具有临床价值；此外，抑制SMOC2基因表达可使压力超负荷模型小鼠的心肌肥厚进展得到延缓，进而预防心力衰竭的发生。因此，检测SMOC2基因表达水平的试剂可用于制备心肌肥厚或心力衰竭检查试剂，SMOC2基因表达抑制剂可用于制备预防、缓解和/或治疗心肌肥厚的药物。

USPTO Abstract

本发明属于生物医药技术领域，具体涉及SMOC2的诊断和制药用途。相较于正常人，临床心力衰竭病人心脏中SMOC2基因表达水平升高，SMOC2作为标志物在心肌肥厚和心力衰竭诊断中具有临床价值；此外，抑制SMOC2基因表达可使压力超负荷模型小鼠的心肌肥厚进展得到延缓，进而预防心力衰竭的发生。因此，检测SMOC2基因表达水平的试剂可用于制备心肌肥厚或心力衰竭检查试剂，SMOC2基因表达抑制剂可用于制备预防、缓解和/或治疗心肌肥厚的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN120393011A
Jurisdiction
CN
Classification
—
Expires
2025-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Renmin Hospital of Wuhan University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.